Pfizer, Merck detail ops savings; BMS aids Brazil in becoming HIV drugmaker;

> Pfizer ($PFE) reports $65 million in savings at its Kalamazoo site from 2006 to 2009, thanks to solvent recovery. Article

> Merck ($MRK) reports $2.8 billion in "net synergies" since merging with Schering-Plough. Release

> Bristol-Myers Squibb ($BMY) has agreed to a technology transfer with the Brazilian Ministry of Health for HIV treatment Reyataz, putting the South American country on a path to become its own sole source provider. Release

> FDA Commissioner Margaret Hamburg says the agency has been underfunded for decades. Video clip

> Drug distributors now handle 87% of the $307 billion market, up from 82% in 2006. Release

> China has fined two middlemen for attempting to control the market for a blood pressure drug, driving up the price of a medicine subsidized by the government. Story

> Metrics's potent facility in Greenville, NC, now boasts a Capsugel Xcelodose powder micro-doser and automated encapsulator for directly placement of API into capsules. Release

> Packaging line specialist Xyntek says it has integrated machine vision solutions to support global serialization, track and trace and e-Pedigree requirements. Announcement

> Chinese officials have busted another counterfeiting operation in Henan province, this one involving fake asthma capsules sold via telephone and mail. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.